Preclinical studies demonstrated an antitumoral effect in HER-2-overexpressing tumor cells, including breast cancer cells, and in this set of patients, BAY2701439 also revealed efficacy in HER-2-low and T-DM1-resistant tumors [127]. This evidence concerns the gene ERBB2 and breast carcinoma.